Biomotion Sciences Ordinary Shares (SLXN) - Total Liabilities
Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) has total liabilities worth $4.31 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Biomotion Sciences Ordinary Shares to track the company's year-over-year net asset growth rate.
Biomotion Sciences Ordinary Shares - Total Liabilities Trend (2020–2025)
This chart illustrates how Biomotion Sciences Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. See Biomotion Sciences Ordinary Shares free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Biomotion Sciences Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Biomotion Sciences Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
Germany | €18.41 Million |
|
Asian Television Network International Ltd
V:SAT
|
Canada | CA$6.63 Million |
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
Brazil | R$3.98 Billion |
|
NewGenIvf Group Limited Class A Ordinary Shares
NASDAQ:NIVF
|
USA | $6.82 Million |
|
ENGAGE XR HLDGS EO-001
F:6VR
|
Germany | €693.16K |
|
Europejskie Centrum Odszkodowań SA
WAR:EUC
|
Poland | zł94.12 Million |
|
Triad Group PLC
LSE:TRD
|
UK | GBX3.06 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Biomotion Sciences Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biomotion Sciences Ordinary Shares (SLXN) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 14.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomotion Sciences Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual total liabilities of Biomotion Sciences Ordinary Shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.61 Million | -32.69% |
| 2024-12-31 | $6.85 Million | -60.42% |
| 2023-12-31 | $17.31 Million | +5.48% |
| 2022-12-31 | $16.41 Million | +3124.89% |
| 2021-12-31 | $508.92K | +69.98% |
| 2020-12-31 | $299.39K | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more